Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus

被引:0
作者
Pecher, G
Spahn, G
Schirrmann, T
Kulbe, H
Ziegner, M
Schenk, JA
Sandig, V
机构
[1] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany
[2] Humboldt Univ, Charite, AG Mol Gene & Immunotherapy, D-10115 Berlin, Germany
[3] Humboldt Univ, Robert Rossle Klin, Dept Hematol Oncol & Tumorimmunol, D-13125 Berlin, Germany
[4] Univ Potsdam, Dept Biotechnol, D-14476 Golm, Germany
[5] Max Planck Gesell, AG, MDC, D-10392 Berlin, Germany
关键词
mucin (MUC1); cationic liposomes; dendritic cells; gene transfer; adenovirus;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Dendritic cells (DC) as antigen presenting cells play an important role in immunotherapy of cancer. Mucin, encoded by the gene MUC1, is a human tumor antigen expressed in breast, pancreatic and ovarian cancers. Therefore, MUC1-transfected DC would be an attractive tool in constructing cancer vaccines. Materials and Methods: Using two different cationic liposome preparations and, for comparison, a recombinant adenovirus expressing mucin, we tested the efficiency of mucin gene transfer into DC by flow cytometry. We investigated if these transfected DC were able to specifically stimulate autologous peripheral blood lymphocytes (PBL) from healthy donors. Results: Flow cytometry revealed that 5-20% of DC transfected with liposomes Lipofectin (R) and 20-40% of DC transduced with adenovirus expressed the relevant mucin epitopes. The expression of mucin on DC was similar to the expression of mucin found on carcinoma cells. After antigen uptake, DC specifically stimulated autologous PBL. Conclusion: We have shown that cationic liposomal gene transfer into human DC was feasible. We could obtain antigen specific stimulation of PBL at a similar rate as with adenoviral MUC1-transduced DC.
引用
收藏
页码:2591 / 2596
页数:6
相关论文
共 26 条
[1]  
Aicher A, 1997, EXP HEMATOL, V25, P39
[2]   DENDRITIC CELLS GENERATED FROM PERIPHERAL-BLOOD TRANSFECTED WITH HUMAN TYROSINASE INDUCE SPECIFIC T-CELL ACTIVATION [J].
ALIJAGIC, S ;
MOLLER, P ;
ARTUC, M ;
JURGOVSKY, K ;
CZARNETZKI, BM ;
SCHADENDORF, D .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (11) :3100-3107
[3]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[4]  
Butterfield LH, 1998, J IMMUNOL, V161, P5607
[5]   Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity [J].
Celluzzi, CM ;
Mayordomo, JI ;
Storkus, WJ ;
Lotze, MT ;
Falo, LD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :283-287
[6]   Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response [J].
Christ, M ;
Lusky, M ;
Stoeckel, F ;
Dreyer, D ;
Dieterle, A ;
Michou, AI ;
Pavirani, A ;
Mehtali, M .
IMMUNOLOGY LETTERS, 1997, 57 (1-3) :19-25
[7]  
De Bruijn MLH, 1998, CANCER RES, V58, P724
[8]   Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells [J].
Diebold, SS ;
Kursa, P ;
Wagner, E ;
Cotten, M ;
Zenke, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (27) :19087-19094
[9]   High efficiency adenovirus-mediated gene transfer to human dendritic cells [J].
Dietz, AB ;
Vuk-Pavlovic, S .
BLOOD, 1998, 91 (02) :392-398
[10]   MUC-1 EPITHELIAL TUMOR MUCIN-BASED IMMUNITY AND CANCER VACCINES [J].
FINN, OJ ;
JEROME, KR ;
HENDERSON, RA ;
PECHER, G ;
DOMENECH, N ;
MAGARIANBLANDER, J ;
BARRATTBOYES, SM .
IMMUNOLOGICAL REVIEWS, 1995, 145 :61-89